← The patent line

Cupric Sulfate; Manganese Sulfate; Selenious Acid; Zinc Sulfate

Sold as MULTRYS, TRALEMENT · given by intravenous

Ten years or more until it comes off patent
14.9 yr
Until anyone may copy it
Protection runs to 2041-07-01
1
Trials running now
6 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

American Regent Inc
Approval holder
the only company permitted to sell it today
2041-07
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Vitamin D DeficiencyAge-related Macular DegenerationAlcohol Drinking
03

Who is paying for the research

Universitaire Ziekenhuizen KU Leuv
University or hospital
1
Galzu Institute of Research, Teach
University or hospital
1
McMaster University
University or hospital
1

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07332429No trials on record2026 · 228 people · not yet recruiting
Efficacy and Safety of Alcovit in Reducing B

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line